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Purpose. To assess the eﬃcacy and safety of intraprostatic injection of two botulinum neurotoxin type A (BoNT-A) doses for
the treatment of benign prostatic hyperplasia (BPH). Materials and Methods. Men with symptomatic BPH who failed medical
treatment were randomized to receive 100U or 200U of BoNT-A into the prostate. The International Prostatic Symptom Score
(IPSS), maximum flow rate (Qmax), post-void residual volume (PVR), PSA levels and prostate volume before injection and after
3 and 6 months were evaluated. Adverse events were compared between the groups. Results. Thirty four patients were evaluated,
including 17 in the BoNT-A 100U group and 17 in the BoNT-A 200U group. Baseline characteristics were similar in both groups.
Both doses produced significant improvements in IPSS, Qmax and PVR after 3 and 6 months and both doses promoted comparable
eﬀects. Prostate volume was aﬀected by 200U BoNT-A injection only after 6 months of treatment. PSA levels were significantly
aﬀected in the 100U group only after 6 months of treatment. In the 200U group, PSA levels were significantly decreased after 3
and 6 months. The complication rate was similar in both groups. Conclusions. Eﬃcacy and safety of both BoNT-A doses are similar
for BPH treatment in the short term followup.
1. Introduction
Benign prostatic hyperplasia (BPH) is a nonmalignant
enlargement of the prostate that aﬀects men in the adulthood
[1]. The purpose of the treatments is to reduce lower urinary
tract symptoms (LUTS) and prevent complications such
as urinary tract infections, urinary retention, and bladder
dysfunction [2, 3].
Several therapeutic options are available, including
watchful waiting, pharmacological therapy, and surgical
procedures [2–4]. Pharmacological therapy, including 5α-
reductase inhibitors and alpha-adrenergic antagonists, is
the most common treatment for BPH [2, 5–8]. However,
improvement of symptoms is often insuﬃcient and the
impact on the urinary flow is limited. Moreover, side
eﬀects such as dizziness, asthenia, postural hypotension,
decreased libido, and erectile dysfunction can limit its
use [2, 4]. When pharmacological therapy fails, surgical
treatments are usually considered. Despite their high success
rates, their invasiveness and potential side eﬀects such as
bleeding, retrograde ejaculation, urethral stenosis, urinary
incontinence, and erectile dysfunction may be discouraging
[4, 6, 9]. Furthermore, 15–25% of the patients who undergo
surgery do not have satisfactory long-term outcomes [9] and
reoperation is necessary in about 1% annually [6].
Consequently, there has been much interest in alternative
treatments for BPH and during the last decade, botulinum
neurotoxin type A (BoNT-A) has been used to treat LUTS
from diﬀerent etiologies, such as striated sphincter dyssyn-
ergia [10, 11], refractory detrusor overactivity [12, 13], and
sensory bladder disorders [14]. Recently, the eﬀects of BoNT-
A in the prostate have gained attention, and encouraging
results in the treatment of BPH have already been published
[15–21]. Nevertheless, a number of questions remain unan-
swered regarding the use of BoNT-A for the treatment of
BPH, including the best route of administration, sites of
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injection, dose, and treatment impact on prostate volume
and PSA levels. The objective of this study was to assess the
eﬃcacy and safety of two diﬀerent doses of BoNT-A in the
treatment of BPH-associated LUTS.
2. Material andMethods
This study was approved by the Local Ethics Committee
and all participants gave written informed consent. Over a
period of 2 years, men with symptomatic BPH were invited
to participate in this prospective study. Inclusion criteria
were age above 50 years, persistent moderate to severe LUTS
as determined by International Prostatic Symptom Score
(IPSS) >8 after medical therapy with at least one alpha-
adrenergic antagonist, peak urinary flow rate (Qmax) of
no more than 12mL/s, and an enlarged prostate gland on
digital rectal examination. Exclusion criteria were previous
surgery for BPH, urethral stenosis, urinary tract infection,
prostate or bladder cancer, pelvic surgery or radiother-
apy, neurological diseases, use of any bladder or prostate
medications including alpha-blockers, 5-alpha reductase
inhibitors or antimuscarinics for the past three months and
BPH-associated complications requiring surgical treatment
including urinary retention, bladder stone, and bilateral
hydronefrosis.
All patients were bothered by their voiding dysfunction
and willing to undergo surgical treatment for it. They
underwent further evaluation before treatment, including
urinalysis, prostate-specific antigen (PSA), transrectal pro-
static and transabdominal urinary tract sonography, free
uroflowmetry, and measurement of post-void residual vol-
ume (PVR).
Just before the injection procedure, patients were ran-
domized to receive either 100U or 200U of BoNT-A.
2.1. Intervention. Injection procedure: with the patient
lying on the lithotomy position and under cardiovascular
monitoring, local anesthesia was performed with 20mL of
lldocaine 2% gel injected transurethraily and waited for 10-
minutes. The injections were performed using a 22Fr rigid
cystoscope (Storz, Germany) and a 23-gauge needle (Richard
Wolf, Germany).
The two diﬀerent BoNT-A (Botox, Allergan, Irvine, CA,
USA) doses (100U or 200U) were reconstituted with saline
0.9% to a total volume of 5ml. All patients received five
injections of 1mL of the BoNT-A solution, including two
injections in each lateral lobe (one proximal and one distal)
and one injection in the medium lobe. The injection depth
was 7–10mm. After the procedure, patients remained under
observation until they were able to void spontaneously
without hematuria. Oral levofloxacin (500mg once a day)
was administered for five days.
2.2. Followup. Evaluations were performed 3 and 6 months
after treatment and included a clinical assessment of LUTS
with the IPSS score as well as measurement of peak urinary
flow rate, postvoid residual volume, serum PSA levels, and
Table 1: Baseline characteristics of patients treated with intrapro-
static BoNT-A.
BoNT-A 100 UI BoNT-A 200 UI P value
N 17 17
Age (yr) 66 ± 8.8 67 ± 10.0 0.59
IPSS 22.0 ± 6.4 22.0 ± 6.9 0.72
Qmax (mL/s) 8.6 ± 3.1 8.4 ± 3.1 0.87
PVR (mL) 131.8 ± 65.0 121.1 ± 73.7 0.88
Prostate volume (mL) 42.3 ± 18.5 43.1 ± 19.7 0.83
PSA (ng/dL) 3.9 ± 4.1 4.1 ± 2.7 0.86
IPSS: international prostatic symptom score, Qmax: maximum urinary flow
rate, PVR: postvoid residual volume.
prostate volume. The primary endpoint was improvement of
IPSS scores.
2.3. Statistical Analyses. Data were expressed as means ±
standard deviation (SD) and range or absolute values and
fractions. Intergroup changes from baseline of continuous
variables were analyzed with analysis of variance for repeated
measurements. Intragroup comparisons were performed
using the Student’s paired t-test. Fisher’s test was used for
categorical variables. A sample size of 17 in each group has
80% power to detect a diﬀerence between means of 3.00
(units in the IPSS score), at a two-tailed significance level
of 0.05 or less. Data were processed using commercially
available statistical software (GraphPad Prism, version 5.00
for Windows, San Diego, CA, USA).
3. Results
We prospectively enrolled 36 patients in this 6-month open-
label study. Two patients that failed to return for the
follow-up evaluations were excluded. A total of 34 patients
completed the study, including 17 in the BoNT-A 100U
group and 17 in the BoNT-A 200U group. No diﬀerences
were found at baseline between the two groups, including
age, IPSS, Qmax, PVR, PSA, and PV (Table 1).
The comparison between baseline characteristics and
outcome measures 3 and 6 months after treatment are
demonstrated in Table 2. Statistically significant changes in
IPSS, Qmax, and PVR were observed at 3rd and 6th months
evaluations with both doses of BoNT-A (Figures 1, 2, and 3).
PSA levels were significantly reduced after six months of
BoNT-A 100U injection but not after three months. In the
200U group, PSA levels were significantly reduced both after
three and six months.
Prostate volume did not vary significantly in the 100U
group. In the 200U group, PV was significantly reduced only
at the six-month evaluation.
The impact of intraprostatic injection of 100U and 200U
of BoNT-A in IPSS, Qmax, PVR, PSA, and prostate volume
was comparable, as seen in Table 2.
Complications and their management are depicted in
Table 3. No severe complication was observed. Two (5.8%)
patients had transient hematuria requiring bladder irriga-
tion, two (5.8%) had short-term urinary retention, and
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Table 2: Mean and percentage change from baseline of International Prostatic Symptom Score (IPSS), maximum urinary flow rate (Qmax),
pos-void residual volume (PVR), PSA levels and prostate volume after 3 and 6 months of treatment.
BoNT-A 100U Change % BoNT-A 200U Change % P value†
IPSS
Baseline 22.1 ± 6.4 22.8 ± 6.9
3rd month 8.0 ± 4.4∗ −64% 9.5 ± 4.2∗ −58% 0.767
6th month 7.5 ± 4.3∗ −66% 9.2 ± 3.4∗ −60% 0.657
Qmax (mL/s)
Baseline 8.6 ± 3.1 8.4 ± 3.2
3rd month 12.8 ± 3.6∗ 49% 11.2 ± 4.8∗ 33% 0.564
6th month 10.9 ± 3.4∗ 27% 11.4 ± 3.2∗ 36% 0.927
PVR (mL)
Baseline 131.8 ± 65.0 121.1 ± 73.7
3rd mo 39.1 ± 33.5∗ −70% 48.1 ± 24.4∗ −60% 0.466
6th mo 38.5 ± 31.2∗ −69% 51.7 ± 24.7∗ −57% 0.311
PSA (ng/dL)
Baseline 3.9 ± 4.1 4.1 ± 2.7
3rd mo 3.2 ± 3.3 ns −18% 3.0 ± 2.1∗ −27% 0.426
6th mo 3.0 ± 2.5∗ −23% 2.7 ± 1.7∗ −34% 0.421
Prostate volume (mL)
Baseline 42.3 ± 18.5 43.1 ± 19.7
3rd mo 38.9 ± 16.1 ns −8% 39.8 ± 17.7 ns −8% 0.961
6th mo 38.6 ± 16.6 ns −9% 37.8 ± 15.5∗ −13% 0.561
†
Statistical significance between groups (intergroup comparison) (Student’s t-test).
Statistical significance within groups: ∗P < 0.05 versus baseline, ns (not significance versus baseline).
(Repeated measures ANOVA and Dunnett’s posttest).
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Figure 1: Mean IPSS of 34 patients treated with 100 and 200U of
intraprostatic BoNT-A.
two had acute prostatitis (5.8%). One patient who initially
had mild improvement of symptoms developed urinary
retention 5 months after 100U BoNT-A injection, requiring
transurethral resection of the prostate. The complication rate
did not diﬀer between the groups (P = 0.921).When present,
pain was usually mild and no patient needed narcotic
analgesics.
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Figure 2: Mean Qmax of 34 patients treated with 100 and 200U of
intraprostatic BoNT-A.
4. Discussion
The eﬃcacy of BPH treatment is primarily determined by
the magnitude of symptom relief as well as improvement
of urinary flow rates. In the present study, both BoNT-A
doses promoted significant improvement of symptoms and
increased flow rates that continued throughout the followup
period of six months.
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Table 3: Complications after intraprostatic botulinum toxin injection for BPH.
Complication n (%) Post-op Treatment Outcome
Hematuria 2 (5.8%) Immediate Bladder irrigation for 2 hours Resolution
Transient urinary retention 2 (5.8%) Immediate Foley catheter for 5 days Resolution
Persistent urinary retention 1 (2.9%) 5 months TURP Resolution
Prostatitis 2 (5.8%) Immediate Amikacin Resolution
TURP: Transurethral resection of the prostate.
Baseline
0
50
100
150
Months
3 6
100 U
200 U
R
es
id
u
al
 v
ol
u
m
e 
(m
L)
Figure 3: Mean PVR of 34 patients treated with 100 and 200U of
intraprostatic BoNT-A.
Maria et al. [15] pioneered BoNT-A injection as a BPH
therapy in a double-blind, placebo-controlled trial with 30
men who no longer responded to oral medication and
refused surgical treatment. A total of 13 (86.7%) patients
in the treated group and 3 (20.0%) in the control group
had symptomatic improvement at the 2-month follow-up.
Patients in the treatment group had significant improvement
in the maximum urinary flow rate, post-void residual
urine volume, and IPSS score. Furthermore, PSA levels and
prostate volume decreased significantly.
Further studies have documented that intraprostatic
BoNT-A injection is an eﬃcient therapy, capable to improve
LUTS and Qmax, as well as to reduce PVR [17, 21]. Our study
has also shown these benefits up to 6 months after treatment.
Additionally, we recorded that both doses (100U and 200U)
promoted similar eﬀects.
One patient treated with 100U of BoNT-A developed
urinary retention five months after the injection. Baseline
characteristics of this patient included an IPSS score of 23,
maximum flow rate of 3mL/s, PVR of 135mL, and a prostate
volume 88mL. These clinical features characterize a severe
case of BPH, which might explain why he failed BoNT-A
therapy. The patient was treated with transurethral resection
of the prostate with a favorable outcome.
The eﬀect of BoNT-A injection on prostate volume is
controversial. Experimental studies demonstrated general-
ized atrophy and apoptosis of glandular and stromal com-
ponents of the prostate [22–24]. Previous series have shown
diﬀerent rates of prostate volume reduction, ranging from 13
to 54% [15, 16, 19, 21]. Although our study demonstrated
benefits in LUTS and flow rates with both doses, a minor
(12%) reduction of prostate volume was observed only with
the use of 200U of the neurotoxin. Chuang et al. [17]
observed that 12 (29%) of 41 patients treated with of BoNT-
A for BPH did not experience reduction of prostate volume,
yet seven of these men had significant improvement of IPSS
and Qmax. These data suggest that BoNT-A may act on the
dynamic obstructive component of BPH. The neurotoxin
was originally thought to act only by inhibiting acetylcholine
release at the presynaptic neuromuscular junction [25].
Presently, other mechanisms are known to be involved such
as blockage of neuroglandular junctions. It is believed that
it also promotes a decrease of norepinephrine release from
sympathetic endings, leading to the consequent reduction of
alpha-1A adrenoceptor stimulation [26]. Furthermore, in an
experimental model using rats, a dose-dependent decrease in
the expression of alfa-1A adrenoceptors was demonstrated
[27]. This is another possible mechanism aﬀected by BoNT-
A treatment, which may promote a decrease in density of
alfa-1a adrenoceptors, which are known to be increased
several-fold in BPH [28].
Diﬀerent doses (range from 100 to 300U) have been
studied in several series, but there is a lack of consistency
in some studies [15–21]. Some authors suggest that prostate
size might influence the dosage [17, 21], but whether larger
prostates require higher doses has actually not been tested.
Moreover, there is no evidence whether the severity of LUTS
influences the optimal dose. To the best of our knowledge, it
is the first study comparing two diﬀerent doses of BoNT-A.
The procedure has been performed by transperineal,
transrectal and transurethral approaches. We chose the
transurethral route because the vast majority of urologists
are trained on cystoscopic procedures and also because it
permits direct vision and injection in the transition zone
of the prostate. Kuo [21] firstly described the cystoscopic
approach using light general anesthesia or sedation. We have
demonstrated that it is feasible to perform this technique
with local anesthesia. Pain, when present, was mild and no
patient required narcotics in the postoperative period.
Complications were uncommon in our series and seemed
to be related to the urethral manipulation rather than a
direct result of BoNT-A injection. Gross hematuria, although
conservatively managed, was observed in 2 (5.8%) patients.
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Transient urinary retention was observed in 2 (5.8%)
patients, and treated conservatively with an indwelling
catheter for 5 days. Two patients (5.8%) developed acute
prostatitis. As mentioned, these adverse eﬀects seem to be
associated with the route of administration of BoNT-A,
since they are potential complications of any procedure
requiring urethral instrumentation. Series that adopted the
transperineal or transrectal approach did not report such
complications [22–27].
Given the vascular nature of the prostate, systemic
absorption of the toxin could occur. The doses used in
intraprostatic injection of BoNT-A are well below the
presumed fatal dose. To our knowledge, no systemic com-
plications have been reported after intraprostatic injections,
even with 300U of BoNT-A [18].
Kuo injected 200U of BoNT-A in the prostate of ten
poor surgical candidates, with BPH and urinary retention
or large postvoid residual volume. All patients improved
spontaneous voiding after treatment. Both voiding pressure
and postvoid residual volume were significantly decreased
after treatment. Total prostate volume was significantly
reduced and maximal flow rate was significantly increased
after treatment [21]. Our study showed that the cystoscopic
route can be performed using local anesthesia, which may
contribute to further decrease treatment risks. Despite our
encouraging results, large-scale, randomized studies with
long-term followup are needed to determine the best delivery
route, sites of injection, suitable dosing as well as the long-
term eﬀects. Studies comparing its cost eﬀectiveness with
that of pharmacological and traditional surgical modalities
are also necessary. Finally, due to its action on cell prolif-
eration, apoptosis, and aﬀerent pathways, the potential role
of BoNT-A in the treatment of prostate cancer and chronic
pelvic pain may be studied in the future.
5. Conclusion
Transurethral intraprostatic BoNT-A injection is a simple
and safe therapy for men with symptomatic BPH. Eﬃcacy
and safety of 100U and 200U BoNT-A doses are similar.
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